bifeprunox has been researched along with aripiprazole in 18 studies
| Studies (bifeprunox) | Trials (bifeprunox) | Recent Studies (post-2010) (bifeprunox) | Studies (aripiprazole) | Trials (aripiprazole) | Recent Studies (post-2010) (aripiprazole) |
|---|---|---|---|---|---|
| 30 | 1 | 12 | 2,989 | 509 | 1,788 |
| Protein | Taxonomy | bifeprunox (IC50) | aripiprazole (IC50) |
|---|---|---|---|
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 0.78 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0158 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 1.945 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.38 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.17 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.42 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.8572 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antonio, CB; Barreiro, EJ; Fraga, CA; Grazziottin, LR; Menegatti, R; Neves, G; Noël, F; Rates, SM; Vieira, RO | 1 |
| Pettersson, F; Pontén, H; Sonesson, C; Waters, N; Waters, S | 1 |
| Blackwell, W; Brockel, B; Campbell, JB; Rosamond, J; Steelman, G; Urbanek, RA; Wesolowski, SS; Widzowski, DV; Wu, Y; Xiong, H; Zhang, M | 1 |
| Albert, JS; Johnstone, S | 1 |
| Assié, MB; Carilla-Durand, E; Cosi, C; Leduc, N; Maraval, M; Newman-Tancredi, A; Ormiere, AM | 1 |
| Dekeyne, A; Iob, L; Millan, MJ; Péglion, JL | 1 |
| Corsini, GU; Maggio, R; Millan, MJ; Novi, F | 1 |
| Forbes, RA; Kikuchi, T; Kitagawa, H; McQuade, RD; Stark, A; Tadori, Y | 1 |
| Arnt, J; Dahan, L; Haddjeri, N; Hertel, P; Husum, H; Mnie-Filali, O | 1 |
| Aliaga, M; Assié, MB; Barbara, M; Bardin, L; Carilla-Durand, E; Malfètes, N; Maraval, M; Newman-Tancredi, A | 1 |
| Seeman, P | 1 |
| Arnt, J; Bétry, C; Etievant, A; Haddjeri, N | 1 |
| Auclair, AL; Barret-Grévoz, C; Barreto, M; Depoortère, R; Kleven, MS; Newman-Tancredi, A | 1 |
| Gyertyán, I; Kiss, B; Román, V; Sághy, K; Szombathelyi, Z | 1 |
| De Santis, M; Deng, C; Huang, XF; Lian, J; Pan, B | 1 |
| Deng, C; Huang, XF; Lian, J; Pan, B | 1 |
| Deng, C; Huang, XF; Pan, B | 2 |
1 review(s) available for bifeprunox and aripiprazole
| Article | Year |
|---|---|
Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective.
Topics: Allosteric Regulation; Chemistry, Pharmaceutical; Humans; Ligands; Structure-Activity Relationship | 2017 |
17 other study(ies) available for bifeprunox and aripiprazole
| Article | Year |
|---|---|
Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Cell Line; Humans; Ligands; Male; Mice; Piperazines; Pyrazoles; Rats; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia | 2010 |
Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Binding, Competitive; Cell Line; Corpus Striatum; Dopamine; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Discovery; Drug Evaluation, Preclinical; Humans; Ligands; Male; Models, Chemical; Molecular Structure; Motor Activity; Piperazines; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2010 |
Synthesis and SAR of aminothiazole fused benzazepines as selective dopamine D2 partial agonists.
Topics: Animals; Antipsychotic Agents; Benzazepines; Biological Assay; Disease Models, Animal; Dopamine Agonists; Drug Partial Agonism; Humans; Inhibitory Concentration 50; Molecular Structure; Protein Binding; Rats; Receptors, Dopamine D2; Structure-Activity Relationship | 2013 |
Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Binding, Competitive; Cell Line; Clozapine; Dioxanes; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Haloperidol; Humans; Male; Piperazines; Prolactin; Quinolones; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Spodoptera; Sulfur Radioisotopes; Tropanes | 2006 |
Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 recept
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzoxazoles; Clozapine; Discrimination Learning; Discrimination, Psychological; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Male; Oxazines; Piperazines; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2007 |
Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation.
Topics: Adenylyl Cyclases; Animals; Antipsychotic Agents; Aripiprazole; Benzamides; Benzoxazoles; Carrier Proteins; Chlorocebus aethiops; Clozapine; COS Cells; Cricetinae; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Piperazines; Piperidines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Transfection | 2007 |
Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.
Topics: Animals; Aripiprazole; Benzoxazoles; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Ergolines; Humans; Piperazines; Quinolones; Radioligand Assay; Receptors, Dopamine D2; Schizophrenia | 2007 |
Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Apomorphine; Aripiprazole; Benzoxazoles; Dopamine; Dopamine D2 Receptor Antagonists; Electroshock; Haloperidol; Male; Neurons; Piperazines; Pyridines; Quinolones; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Ultrasonics; Ventral Tegmental Area; Vocalization, Animal | 2009 |
The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Benzofurans; Benzoxazoles; Benzylamines; Blood Glucose; Clozapine; Corticosterone; Cyclopentanes; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Thiazoles | 2008 |
Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole.
Topics: Animals; Aripiprazole; Benzoxazoles; CHO Cells; Cricetinae; Cricetulus; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Humans; Piperazines; Protein Binding; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2008 |
Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
Topics: Action Potentials; Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Interactions; Indoles; Male; Neurons; Piperazines; Piperidines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D3; Sulfones; Tetrahydronaphthalenes; Ventral Tegmental Area | 2009 |
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Benzamides; Benzodiazepines; Benzoxazoles; Catalepsy; Clozapine; Dibenzothiazepines; Dioxanes; Dopamine Antagonists; Female; Haloperidol; Macaca fascicularis; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Remoxipride; Risperidone; Serotonin Receptor Agonists; Thiazoles; Tropanes; Video Recording | 2009 |
Cariprazine (RGH-188), a D₃-preferring dopamine D₃/D₂ receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Cocaine-Related Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Haloperidol; Male; Piperazines; Quinolones; Rats; Rats, Long-Evans; Receptors, Dopamine D2; Secondary Prevention; Substance-Related Disorders | 2013 |
Different effects of bifeprunox, aripiprazole, and haloperidol on body weight gain, food and water intake, and locomotor activity in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Drinking Behavior; Feeding Behavior; Haloperidol; Male; Motor Activity; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Weight Gain | 2014 |
Aripiprazole Increases the PKA Signalling and Expression of the GABAA Receptor and CREB1 in the Nucleus Accumbens of Rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Haloperidol; Male; Nucleus Accumbens; Piperazines; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Signal Transduction | 2016 |
Aripiprazole and Haloperidol Activate GSK3β-Dependent Signalling Pathway Differentially in Various Brain Regions of Rats.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; beta Catenin; Blotting, Western; Brain; Dishevelled Proteins; Glycogen Synthase Kinase 3 beta; Haloperidol; Male; Phosphorylation; Piperazines; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Signal Transduction | 2016 |
Chronic administration of aripiprazole activates GSK3β-dependent signalling pathways, and up-regulates GABAA receptor expression and CREB1 activity in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Cyclic AMP Response Element-Binding Protein; Glycogen Synthase Kinase 3 beta; Haloperidol; Piperazines; Prefrontal Cortex; Rats; Signal Transduction; Up-Regulation | 2016 |